193 related articles for article (PubMed ID: 35842694)
1. Targeting IL-6 by engineered Lactococcus lactis via surface-displayed affibody.
Zahirović A; Berlec A
Microb Cell Fact; 2022 Jul; 21(1):143. PubMed ID: 35842694
[TBL] [Abstract][Full Text] [Related]
2. p19-Targeting ILP Protein Blockers of IL-23/Th-17 Pro-Inflammatory Axis Displayed on Engineered Bacteria of Food Origin.
Škrlec K; Zadravec P; Hlavničková M; Kuchař M; Vaňková L; Petroková H; Křížová L; Černý J; Berlec A; Malý P
Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 29966384
[TBL] [Abstract][Full Text] [Related]
3. Engineered and wild-type L. lactis promote anti-inflammatory cytokine signalling in inflammatory bowel disease patient's mucosa.
Simčič S; Berlec A; Stopinšek S; Štrukelj B; Orel R
World J Microbiol Biotechnol; 2019 Feb; 35(3):45. PubMed ID: 30810891
[TBL] [Abstract][Full Text] [Related]
4. Lactic Acid Bacteria with Concomitant IL-17, IL-23 and TNFα- Binding Ability for the Treatment of Inflammatory Bowel Disease.
Kosler S; Strukelj B; Berlec A
Curr Pharm Biotechnol; 2017; 18(4):318-326. PubMed ID: 28190384
[TBL] [Abstract][Full Text] [Related]
5. Secretion and surface display of binders of IL-23/IL-17 cytokines and their receptors in Lactococcus lactis as a therapeutic approach against inflammation.
Plavec TV; Klemenčič K; Kuchař M; Malý P; Berlec A
Eur J Pharm Sci; 2023 Nov; 190():106568. PubMed ID: 37619953
[TBL] [Abstract][Full Text] [Related]
6. Engineering recombinant Lactococcus lactis as a delivery vehicle for BPC-157 peptide with antioxidant activities.
Škrlec K; Ručman R; Jarc E; Sikirić P; Švajger U; Petan T; Perišić Nanut M; Štrukelj B; Berlec A
Appl Microbiol Biotechnol; 2018 Dec; 102(23):10103-10117. PubMed ID: 30191288
[TBL] [Abstract][Full Text] [Related]
7. Dual Functionalized
Zahirović A; Plavec TV; Berlec A
Front Bioeng Biotechnol; 2022; 10():822823. PubMed ID: 35155394
[TBL] [Abstract][Full Text] [Related]
8. Engineered
Plavec TV; Kuchař M; Benko A; Lišková V; Černý J; Berlec A; Malý P
Microorganisms; 2019 May; 7(5):. PubMed ID: 31137908
[No Abstract] [Full Text] [Related]
9. Effects in the use of a genetically engineered strain of Lactococcus lactis delivering in situ IL-10 as a therapy to treat low-grade colon inflammation.
Martín R; Chain F; Miquel S; Natividad JM; Sokol H; Verdu EF; Langella P; Bermúdez-Humarán LG
Hum Vaccin Immunother; 2014; 10(6):1611-21. PubMed ID: 24732667
[TBL] [Abstract][Full Text] [Related]
10. Cell surface display system for Lactococcus lactis: a novel development for oral vaccine.
Raha AR; Varma NR; Yusoff K; Ross E; Foo HL
Appl Microbiol Biotechnol; 2005 Jul; 68(1):75-81. PubMed ID: 15635459
[TBL] [Abstract][Full Text] [Related]
11. Evasin-displaying lactic acid bacteria bind different chemokines and neutralize CXCL8 production in Caco-2 cells.
Škrlec K; Pucer Janež A; Rogelj B; Štrukelj B; Berlec A
Microb Biotechnol; 2017 Nov; 10(6):1732-1743. PubMed ID: 28736998
[TBL] [Abstract][Full Text] [Related]
12. Development of Recombinant Lactococcus lactis Displaying Albumin-Binding Domain Variants against Shiga Toxin 1 B Subunit.
Zadravec P; Marečková L; Petroková H; Hodnik V; Perišić Nanut M; Anderluh G; Štrukelj B; Malý P; Berlec A
PLoS One; 2016; 11(9):e0162625. PubMed ID: 27606705
[TBL] [Abstract][Full Text] [Related]
13. Production, secretion and purification of a correctly folded staphylococcal antigen in Lactococcus lactis.
Samazan F; Rokbi B; Seguin D; Telles F; Gautier V; Richarme G; Chevret D; Varela PF; Velours C; Poquet I
Microb Cell Fact; 2015 Jul; 14():104. PubMed ID: 26178240
[TBL] [Abstract][Full Text] [Related]
14. Preventative delivery of IL-35 by Lactococcus lactis ameliorates DSS-induced colitis in mice.
Wang J; Tian M; Li W; Hao F
Appl Microbiol Biotechnol; 2019 Oct; 103(19):7931-7941. PubMed ID: 31456001
[TBL] [Abstract][Full Text] [Related]
15. Expression of biologically active murine interleukin-18 in Lactococcus lactis.
Feizollahzadeh S; Khanahmad H; Rahimmanesh I; Ganjalikhani-Hakemi M; Andalib A; Sanei MH; Rezaei A
FEMS Microbiol Lett; 2016 Nov; 363(21):. PubMed ID: 27864297
[TBL] [Abstract][Full Text] [Related]
16. Lactococcus lactis carrying the pValac eukaryotic expression vector coding for IL-4 reduces chemically-induced intestinal inflammation by increasing the levels of IL-10-producing regulatory cells.
Souza BM; Preisser TM; Pereira VB; Zurita-Turk M; de Castro CP; da Cunha VP; de Oliveira RP; Gomes-Santos AC; de Faria AM; Machado DC; Chatel JM; Azevedo VA; Langella P; Miyoshi A
Microb Cell Fact; 2016 Aug; 15(1):150. PubMed ID: 27576902
[TBL] [Abstract][Full Text] [Related]
17. Insertion of single-chain variable fragment (scFv) peptide linker improves surface display of influenza hemagglutinin (HA1) on non-recombinant Lactococcus lactis.
Jee PF; Chen FS; Shu MH; Wong WF; Abdul Rahim R; AbuBakar S; Chang LY
Biotechnol Prog; 2017 Jan; 33(1):154-162. PubMed ID: 27802566
[TBL] [Abstract][Full Text] [Related]
18. Secretion of recombinant xylanase in Lactococcus lactis using signal peptides Usp45 and Spk1.
Roslan AM; Mustafa Kamil A; Chandran C; Song AA; Yusoff K; Abdul Rahim R
Biotechnol Lett; 2020 Sep; 42(9):1727-1733. PubMed ID: 32335791
[TBL] [Abstract][Full Text] [Related]
19. Receptor binding domain of Escherichia coli F18 fimbrial adhesin FedF can be both efficiently secreted and surface displayed in a functional form in Lactococcus lactis.
Lindholm A; Smeds A; Palva A
Appl Environ Microbiol; 2004 Apr; 70(4):2061-71. PubMed ID: 15066797
[TBL] [Abstract][Full Text] [Related]
20. Secretion of an immunoreactive single-chain variable fragment antibody against mouse interleukin 6 by Lactococcus lactis.
Shigemori S; Ihara M; Sato T; Yamamoto Y; Nigar S; Ogita T; Shimosato T
Appl Microbiol Biotechnol; 2017 Jan; 101(1):341-349. PubMed ID: 27722916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]